Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Back to the forum  2018-07-23 17:15 CEST (UTC+2h)

...and much more [BE/BA News]

posted by ElMaestro - Denmark, 2017-04-29 15:58  - Posting: # 17281
Views: 1,840

Hi Hötzi,

yes, and there's no doubt there's going to be lots of interesting news in the coming years.
There's a WP dedicated to M&S which is picking up speed (there wouldn't be one if the general attitude towards M&S was entirely negative, would there?!?), and the OIP guideline from 2009 is also under revision which will create obstacles for some and pave ways forward for others.

And I was asked yesterday by an agency employee if we need a dedicated data integrity guideline and/or WP. I think this question was posed in view of the recent horror stories about BE CROs.

if (3) 4

Best regards,

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,547 posts in 3,941 threads, 1,190 registered users;
online 9 (1 registered, 8 guests [including 7 identified bots]).

[The] impatience with ambiguity can be criticized in the phrase:
absence of evidence is not evidence of absence.    Carl Sagan

BEBAC Ing. Helmut Schütz